Observed and Predicted Total Pubertal Growth during Treatment with Growth Hormone in Adolescents with Idiopathic Growth Hormone Deficiency, Turner Syndrome, Short Stature, Born Small for Gestational Age and Idiopathic Short Stature: KIGS Analysis and Review

2011 ◽  
Vol 75 (6) ◽  
pp. 423-432 ◽  
Author(s):  
Michael B. Ranke ◽  
Anders Lindberg ◽  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Deficiency ◽  
Short Stature ◽  
Turner Syndrome ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Idiopathic Short Stature ◽  
Hormone Deficiency ◽  
Pubertal Growth ◽  
Idiopathic Growth Hormone Deficiency

scholarly journals Adherence to treatment in children with growth hormone deficiency, small for gestational age and Turner syndrome in Mexico: results of the Easypod™ connect observational study (ECOS)

2020 ◽  
Vol 43 (10) ◽  
pp. 1447-1452
Author(s):  
A. Blanco-López ◽  
C. Antillón-Ferreira ◽  
E. Saavedra-Castillo ◽  
M. Barrientos-Pérez ◽  
H. Rivero-Escalante ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Observational Study ◽  
Growth Hormone Deficiency ◽  
Turner Syndrome ◽  
Gestational Age ◽  
Small For Gestational Age ◽  
Hormone Deficiency ◽  
Height Velocity ◽  
Electronic Injection

Abstract Background Assessing adherence to growth hormone (GH) is challenging. The Easypod™ connect device delivers pre-set doses of recombinant human GH (r-hGH) and stores a digital record of adherence that can be shared with healthcare provider. We assessed adherence to r-hGH delivered with Easypod™ according to the approved pediatric indications for r-hGH: growth hormone deficiency (GHD), born small for gestational age (SGA) who failed to show catch-up growth and Turner syndrome (TS). Methods ECOS (NCT01555528) was a multicenter (24 countries), 5-year, longitudinal, observational study, which aimed to evaluate country-specific adherence to r-hGH therapy prescribed via the Easypod™ electronic injection device. The primary endpoint was yearly adherence. Secondary endpoints were height velocity, height velocity standard deviation scores (SDS), height, height SDS and IGF-1 concentrations. Clinical and auxological data were obtained from medical records and adherence from Easypod™ logs. Results This study included 147 Easypod™-naïve Mexican children assessed during 3 years (mean age: 9.96 ± 3.41 years, 56.8% boys, mean height SDS at baseline: − 2.17 ± 0.97): 118 with GHD, 24 SGA and 5 with TS. A total of 105 (71.4%) patients were GH naïve. Overall median adherence was > 90% over the first year of treatment and > 80% at 3 years. Adherence was not different by r-hGH indication or between GH-naïve or experienced patients. At 1-year follow-up, mean change in height SDS was 0.57 ± 0.34, whereas mean height velocity SDS was 2.85 ± 2.51. In all, 84.7% patients had normal IGF-1 concentrations at 1-year follow-up. Adherence was associated with change in height SDS (r = 0.239, p = 0.005) and height velocity SDS (r = 0.194, p = 0.027). Conclusion Adherence rates with the Easypod™ device are high and maintained over time in GHD, SGA and TS Easypod™-naïve Mexican patients. High adherence is associated with better outcomes. Easypod™ assists physicians in monitoring adherence to r-hGH.

Sign in / Sign up

Export Citation Format

Share Document